90,577 Shares in DexCom, Inc. (NASDAQ:DXCM) Acquired by FORA Capital LLC

FORA Capital LLC bought a new stake in DexCom, Inc. (NASDAQ:DXCM) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 90,577 shares of the medical device company’s stock, valued at approximately $6,072,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Jennison Associates LLC boosted its holdings in shares of DexCom by 1,683.2% during the third quarter. Jennison Associates LLC now owns 6,932,899 shares of the medical device company’s stock worth $464,782,000 after purchasing an additional 6,544,102 shares during the period. Westfield Capital Management Co. LP boosted its stake in shares of DexCom by 44.6% during the 3rd quarter. Westfield Capital Management Co. LP now owns 2,842,057 shares of the medical device company’s stock valued at $190,532,000 after buying an additional 876,739 shares during the period. Canada Pension Plan Investment Board grew its holdings in shares of DexCom by 189.1% during the 2nd quarter. Canada Pension Plan Investment Board now owns 665,646 shares of the medical device company’s stock valued at $75,471,000 after acquiring an additional 435,401 shares in the last quarter. Intech Investment Management LLC increased its stake in shares of DexCom by 2,083.0% in the third quarter. Intech Investment Management LLC now owns 387,330 shares of the medical device company’s stock worth $25,967,000 after acquiring an additional 369,587 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA raised its holdings in shares of DexCom by 16.9% during the second quarter. Massachusetts Financial Services Co. MA now owns 2,439,033 shares of the medical device company’s stock worth $276,538,000 after acquiring an additional 353,019 shares in the last quarter. Institutional investors and hedge funds own 97.75% of the company’s stock.

Insider Transactions at DexCom

In related news, COO Jacob Steven Leach sold 746 shares of the stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $51,585.90. Following the completion of the sale, the chief operating officer now owns 264,915 shares in the company, valued at approximately $18,318,872.25. This trade represents a 0.28 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the transaction, the executive vice president now owns 75,451 shares in the company, valued at $5,217,436.65. This represents a 0.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 5,431 shares of company stock worth $399,319 over the last three months. 0.30% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

A number of research analysts have commented on the company. Raymond James lowered their target price on DexCom from $115.00 to $99.00 and set a “strong-buy” rating on the stock in a research note on Friday, October 25th. Stifel Nicolaus increased their price objective on DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Oppenheimer cut their price objective on shares of DexCom from $115.00 to $105.00 and set an “outperform” rating on the stock in a research report on Friday, October 25th. Royal Bank of Canada decreased their target price on shares of DexCom from $120.00 to $115.00 and set an “outperform” rating for the company in a research report on Friday, October 25th. Finally, StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a report on Saturday, November 2nd. Seven investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, DexCom currently has a consensus rating of “Moderate Buy” and a consensus target price of $104.59.

DexCom Stock Performance

Shares of NASDAQ DXCM traded down $0.63 during trading hours on Wednesday, hitting $77.31. 200,444 shares of the company’s stock were exchanged, compared to its average volume of 3,923,553. The stock has a market capitalization of $30.20 billion, a price-to-earnings ratio of 46.67, a PEG ratio of 2.38 and a beta of 1.17. The company’s 50-day moving average price is $70.94 and its 200-day moving average price is $88.58. The company has a debt-to-equity ratio of 1.23, a current ratio of 2.46 and a quick ratio of 2.12. DexCom, Inc. has a 1-year low of $62.34 and a 1-year high of $142.00.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.